In Europe's biopharmaceutical sector, already some 20 % of the current medicines are derived from biotechnology, with up to 50 % of new medicines.
Cheana féin, in earnáil bhithchógaisíochta na hEorpa, díorthaítear tuairim agus 20 % de na cógais reatha ó bhiteicneolaíocht, ar cógais nua suas le 50 % díobh.